Forest/Almirall's COPD drug set for mid-year filing on positive Phase III
This article was originally published in Scrip
Executive Summary
Forest Laboratories and Almirall's chronic obstructive pulmonary disease (COPD) therapy has met the primary endpoints in its third Phase III trial, say the companies. Regulatory submissions in both Europe and the US for aclidinium bromide monotherapy are planned for mid 2011.